A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases.
Learn MoreJoin us in creating the future of eye care!
Our Products
We currently market two innovative prescription eye drops for lowering intraocular pressure (IOP) in glaucoma.
Learn More
Our Research
We are making significant progress in developing new treatments for dry eye and retinal diseases.
Learn More
STOCK Quote
NASDAQ: AERI
$11.47USD
Aug 18, 4:00 PM ET
Latest News
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
DISCOVaerie™ Live!
Visit our virtual destination for the eye care community to get informed and connected.
MORE
CAREERS AT AERIE
We are looking for VISIONaerieS® who share our passion for innovation to protect sight.
MORE
OUR ESG COMMITMENT
Aerie is dedicated to environmental stewardship, social responsibility, and good corporate governance.
MORE